Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma—a practical guideline

J Thiele, T K Zirbes, H M Kvasnicka, R Fischer

Abstract

Aims—To provide practical guidelines for the differentiation between benign and malignant focal lymphoid aggregates (lymphoid nodules) in routinely referred bone marrow trephine biopsies, using a synoptic approach including clinical data and histological workup.

Methods—For easy identification of very small lymphoid infiltrates the chloroacetate esterase stain was applied as a screening procedure. This allowed the identification of 491 formalin fixed, paraffin wax embedded specimens with one or more lymphoid nodules. Examination of lymphoid infiltrates included such variables as histotopography, demarcation, cytology, reticulin fibres, and immunohistochemistry with a set of monoclonal antibodies (CD20, CD45R, CD45R0, CD3, CD43). Evaluation of clinical and morphological data was carried out independently. In case of malignant lymphomas, a correlation with corresponding lymph node findings was made.

Results—352 patients had benign focal lymphoid aggregates usually associated with systemic autoimmune diseases, chronic myeloproliferative disorders, toxic myelopathy, and viral infections. Discrete nodular infiltrates of (small cell) malignant lymphomas (n = 93) simulating benign hyperplasia were found in chronic lymphocytic leukaemia, germinal centre cell lymphomas (CB-CC), and lymphoplasmacytic/cytoid lymphomas (LPD). In addition to immunoreactivity, certain histological variables proved distinctive. These were: (1) histotopography, that is, localisation of the lymphoid aggregates within the bone marrow space; (2) relation to the surrounding tissue: margination or interstitial spillage of lymphoid cells; and (3) increase in reticulin fibres.

Conclusions—A combined diagnostic procedure identifying several distinctive features, in particular histotopography and immunohistochemistry, provides a most promising way of discriminating reactive from neoplastic lymphoid nodules in the bone marrow.

(J Clin Pathol 1999;52:294–300)

Keywords: lymphoid nodules; reactive neoplastic lesions; bone marrow; trephine biopsies

There is still a conflict of opinion over the distinction between benign (reactive) focal lymphoid aggregates (nodules, hyperplasia) and infiltrates of malignant lymphomas in bone marrow tissue.1–4 This is one of the major continuing problems in haematopathology. In daily routine, the pathologist is frequently confronted by focal lymphoid marrow aggregates of uncertain origin. These lesions may be found in samples derived either from patients with a known lymphoproliferative disorder during a primary or secondary staging procedure, or in specimens with the clinical question of malignant lymphoma, though without appropriate lymph node histology. Moreover, controversy may arise over whether extensive lymphoid nodules accompanying chronic myeloproliferative disorders are only a reactive feature.7–10 Finally, many focal lymphoid lesions within the bone marrow lack a relation with an established disorder. In the majority of cases these are associated with the rather ill defined finding of anaemia, particularly in a geriatric population.7,8

Our purpose in this study was to investigate systematically the occurrence and relevance of focal lymphoid aggregates in bone marrow trephine biopsy samples retained from routinely referred material. In a synoptic review of the underlying clinical conditions and marrow features, including in particular histotopography, content of reticulin fibres, and immunohistochemistry, we tried to distinguish between benign lymphoid nodules and focal manifestations of malignant lymphomas of the non-Hodgkin and Hodgkin type.

Methods

Patients and bone marrow biopsies

Selection of bone marrow samples included a three step procedure. First, a review of about 18 000 representative trephine biopsies drawn from our files and stained by naphthol-AS-D-chloroacetate esterase showed more than 491 specimens with one or several prominent lymphoid aggregates of different size, shape, and cytology. Second, these lymphoid nodules were classified into reactive or neoplastic lesions according to histological appearance and results of immunostaining without knowledge of the patient’s identity. Third, the diagnosis was reconsidered in a retrospective analysis of the clinical data. In cases of non-Hodgkin and Hodgkin lymphoma, lymph node pathology and bone marrow findings were compared and correlated with the clinical status. High grade
collaboration was possible because our institution is a lymphoma referral centre. Subtyping of NHL was performed according to the updated Kiel classification. Patients bearing benign focal lymphoid infiltrates were re-evaluated with respect to their underlying condition.

## BIOPSY TECHNIQUES AND HISTOLOGICAL PREPARATION

Following a representative trephine biopsy from the posterior iliac crest, fixation was performed in an aldehyde solution for 12 to 24 hours (2 ml 25% glutaraldehyde, 3 ml 37% formaldehyde, 1.58 g calcium acetate, and distilled water to 100 ml). Further processing included decalcification for three to four days in 10% buffered EDTA pH 7.2–7.4, paraffin embedding, and employment of several staining techniques: Giemsa, PAS (periodic acid Schiff reaction), naphthol-AS-D-chloroacetate esterase, Perl’s reaction for iron, and the silver impregnation method after Gomori.

## IMMUNOSTAINING

Pretreatment of mounted paraffin sections included dewaxing through xylene and alcohol and rinsing in buffer (50 mM Tris–HCl, pH 7.6) for 30 minutes. Thereafter sections were stained according to the alkaline phosphatase–anti-alkaline phosphatase (APAAP) technique applying monoclonal antibodies listed in table 1 in proper concentrations (1:50–100) and variable incubation times (30 minutes to one hour), using new fuchsin as the alkaline phosphatase substrate. To demonstrate monoclonal immunoglobulin expression, the peroxidase–antiperoxidase (PAP) method was applied in combination with polyclonal antibodies, as previously described in more detail.

### Results

The focal lymphoid aggregates found in our bone marrow trephine biopsies varied significantly in frequency, size, localisation, cytological appearance, reticulin fibre content, and immunoreactivity. Features that allowed ready differentiation between benign lymphoid nodules and non-Hodgkin/Hodgkin lymphoma were as follows: first, true lymphoid follicles (fig 1A) with germinal centres cuffing central marrow vessels in 21 patients with an autoimmune disorder (table 2); second, in 46 patients focal accumulations of large blastic (centroblastic–immunoblastic) or polymorphous cells were observed in non-Hodgkin lymphomas of high malignancy; and third, nodular ill defined lesions with increased fibres, vascular proliferation, T lymphocytes, and plasma cells suggested angioimmunoblastic (AILD), while others containing atypical histiocytic cells and mononuclear Hodgkin and Reed-Sternberg cells were consistent with Hodgkin lymphoma. It should be emphasised that in these cases histopathology was compatible with the diagnosis.

In contrast with those findings, in 93 patients it was difficult to assess solitary or multiple infiltrates (up to eight in one sectional profile) composed of small to intermediate lymphoid cells and simulating benign lymphoid nodules (table 3). The procedures that were especially useful in classifying these were histotopography (localisation and infiltration pattern), demarcation, fibre content, and immunostaining. To reach a correct final diagnosis these features should be considered in a synoptic evaluation, as outlined in more detail in table 4. In this context we should emphasise that every malignant lymphoid infiltrate had a corresponding lymph node diagnosis of lymphoma.

Lymphoid aggregates of reactive origin show a tendency to central localisation and usually have a clearly defined border margin consisting of a mixture of B and T lymphocytes (fig 1, C–F). A superficial/subcortical infiltrate in the age related adipose tissue or an endosteal tapestry-like (paratrabeicular) involvement was not detectable in benign lymphoid nodules, but regularly encountered in CB-CC non-Hodgkin lymphoma (figs 1B, 2C–E) and also in several cases of lymphoplasmacytic/cytoid (LPI) non-Hodgkin lymphoma. An ill defined border of a nodular lymphoid aggregate with spillage of single lymphocytes between the adipocytes or an Indian-file-like interstitial extension is often recognised in non-Hodgkin lymphoma (figs 2A, 3A, B), but never prominent in reactive hyperplasia. This overspill of lymphocytes into internodular areas is can be shown by applying immunohistochemical methods (figs 2B, 3A). A moderate to pronounced increase in reticulin fibre density within the infiltrates is limited to certain subtypes of non-Hodgkin lymphoma such as CB-CC, LPI (figs 2F, 3C), and T cell lymphomas (AILD), in addition to Hodgkin lymphoma. Contrasting with this finding, chronic lymphocytic leukaemia, with a strictly nodular central infiltration pattern, is not characterised by a conspicuous meshwork of reticulin. On the other hand, in HIV myelopathy the inflammatory reaction of the bone marrow stroma is often accompanied by a borderline to moderate increase in fibres. Although the above mentioned indices may be very helpful in distinguishing reactive from neoplastic lymphoid nodules, immunostaining with a set of easy to handle monoclonal antibodies (table 1) presents an invaluable diagnostic tool. This implies first, the demonstration of a uniform

### Table 1 Monoclonal antibodies according to the CD classification used in the present study

<table>
<thead>
<tr>
<th>Antibody</th>
<th>CD classification</th>
<th>Reacting cell population</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>L26</td>
<td>CD 20</td>
<td>B lymphocytes</td>
<td>Dako Diagnostika, Hamburg</td>
</tr>
<tr>
<td>4 KB5</td>
<td>CD 45 R</td>
<td>B lymphocytes</td>
<td>Dako Diagnostika, Hamburg</td>
</tr>
<tr>
<td>LCA</td>
<td>CD 45</td>
<td>Granulo-lymphocytes</td>
<td>Dako Diagnostika, Hamburg</td>
</tr>
<tr>
<td>UCHL-1</td>
<td>CD 45 RO</td>
<td>T lymphocytes and mono-histiocytes</td>
<td>Dako Diagnostika, Hamburg</td>
</tr>
<tr>
<td>PC3/188A</td>
<td>CD 3</td>
<td>T lymphocytes and mono-histiocytes</td>
<td>Dako Diagnostika, Hamburg</td>
</tr>
<tr>
<td>Ki-1</td>
<td>CD 30</td>
<td>Activated lymphoid cells, Reed-Sternberg cells</td>
<td>Dako Diagnostika, Hamburg</td>
</tr>
<tr>
<td>MT1</td>
<td>CD 43</td>
<td>T lymphocytes and myeloid cells</td>
<td>Clonab, Dreieich</td>
</tr>
</tbody>
</table>

---

infiltration pattern consisting of B (or rarely T) lymphocytes in accordance with the subtype of NHL (figs 2C–E; 3A, B, D–F); and second, the presence of immunoglobulin light and heavy chain restrictions which proves to be sufficiently reliable to establish monoclonality, as in LPI non-Hodgkin lymphoma (fig 3G, H). For practical purpose a combination of at least two so called B and T cell markers (table 1) is advisable, since most monoclonal antibodies show variable cross reactivity with other myeloid cells (figs 2D, E; 3E, F). Relevant features aiding the differentiation between benign lymphoid nodules and non-Hodgkin/Hodgkin lymphoma are summarised in table 4.

Finally, when comparing the histological appearance of non-Hodgkin lymphoma in lymph nodes and bone marrow by applying the updated Kiel classification, in seven cases a discordance was evident. These disparate subtypes included mostly a CB-CC differentiation pattern in the lymph nodes contrasting with a variable fraction of centrocytes versus centroblasts in the bone marrow, or a lymphocytic non-Hodgkin lymphoma in the marrow versus an LPI in the periphery. Several indetermina-
Table 2  Benign lymphoid nodules (n=352) and underlying disorders presenting in about 18 000 trephine biopsies of the bone marrow

<table>
<thead>
<tr>
<th>I. Systemic autoimmune disorders</th>
<th>II. Chronic myeloproliferative disorders</th>
<th>III. Aplastic anaemia (toxic myelopathy)</th>
<th>IV. Myelodyplastic syndromes</th>
<th>V. Viral infections</th>
<th>VI. Unknown or not evaluable</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Rheumatoid arthritis, lupus erythematosus</td>
<td>(a) Polychaemia vera</td>
<td>(a) Hepatitis (B and C type)</td>
<td>(a) HIV myelopathy (AIDS)</td>
<td>(a) Polyclonal gammopathy</td>
<td>11</td>
</tr>
<tr>
<td>(b) Autoimmune haemolytic anaemia</td>
<td>(b) Idiopathic (primary) myelofibrosis</td>
<td>(b) HIV myelopathy (AIDS)</td>
<td>(b) HIV myelopathy (AIDS)</td>
<td>(b) HIV myelopathy (AIDS)</td>
<td>11</td>
</tr>
<tr>
<td>(c) Idiopathic thrombocytopaenia</td>
<td>(c) Chronic myeloid leukaemia</td>
<td>(c) HIV myelopathy (AIDS)</td>
<td>(c) HIV myelopathy (AIDS)</td>
<td>(c) HIV myelopathy (AIDS)</td>
<td>11</td>
</tr>
<tr>
<td>(d) Hyper-hypophosphataemia (Hashimoto)</td>
<td>(d) Essential (primary) thrombocytopaenia</td>
<td>(d) HIV myelopathy (AIDS)</td>
<td>(d) HIV myelopathy (AIDS)</td>
<td>(d) HIV myelopathy (AIDS)</td>
<td>11</td>
</tr>
<tr>
<td>Number of infiltrates in section profile</td>
<td>Reticulin fibres</td>
<td>Immunostaining techniques</td>
<td>Immunostaining techniques</td>
<td>Immunostaining techniques</td>
<td>Immunostaining techniques</td>
</tr>
<tr>
<td>Number of infiltrates in section profile</td>
<td>Moderate to advanced (except CLL)</td>
<td>Moderate to advanced (except CLL)</td>
<td>Moderate to advanced (except CLL)</td>
<td>Moderate to advanced (except CLL)</td>
<td>Moderate to advanced (except CLL)</td>
</tr>
<tr>
<td></td>
<td>Borderline to minimal (except HIV myelopathy)</td>
<td>Borderline to minimal (except HIV myelopathy)</td>
<td>Borderline to minimal (except HIV myelopathy)</td>
<td>Borderline to minimal (except HIV myelopathy)</td>
<td>Borderline to minimal (except HIV myelopathy)</td>
</tr>
<tr>
<td></td>
<td>Uniform pattern with predominance of B or T lymphocytes; expression of monotypic (cytoplasmic) immunoglobulins</td>
<td>Uniform pattern with predominance of B or T lymphocytes; expression of monotypic (cytoplasmic) immunoglobulins</td>
<td>Uniform pattern with predominance of B or T lymphocytes; expression of monotypic (cytoplasmic) immunoglobulins</td>
<td>Uniform pattern with predominance of B or T lymphocytes; expression of monotypic (cytoplasmic) immunoglobulins</td>
<td>Uniform pattern with predominance of B or T lymphocytes; expression of monotypic (cytoplasmic) immunoglobulins</td>
</tr>
</tbody>
</table>

Table 3  Focal bone marrow infiltrates (n=139) in malignant lymphomas: subtypes according to the Kiel classification

<table>
<thead>
<tr>
<th>Lymphocytic (chronic lymphocytic leukaemia, CLL)</th>
<th>Centroblast-centrocytic (CB-CC)</th>
<th>Centroblast (CB)</th>
<th>Immunoblastic (IB)</th>
<th>Burkitt type</th>
<th>T cell lymphoma (angioimmunoblastic, AILD)</th>
<th>Hodgkin lymphoma (HL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>49</td>
<td>12</td>
<td>8</td>
<td>3</td>
<td>8</td>
<td>15</td>
</tr>
</tbody>
</table>

Discussion

In recent years a wealth of data has accumulated on the clinical importance of making a clear cut distinction between benign lymphoid nodules and focal infiltrations by non-Hodgkin lymphoma and Hodgkin lymphoma in the bone marrow. Conventional morphological studies may provide clues to the nature of the lymphoid lesions in those cases, where either large blastic or grossly abnormal cells or a so called packed marrow with an extensive growth pattern are observed. Considerable diagnostic difficulties arise, however, when lymphoid cell involvement is strictly focal and composed of small to intermediate sized elements. Infiltrates of this kind may present early stages of non-Hodgkin lymphoma, especially lymphocytic lymphoma (chronic lymphocytic leukaemia) with a central localisation simulating reactive lesions. In these cases the differentiation has to be unequivocal, because the infiltration pattern of chronic lymphocytic leukaemia has repeatedly been shown to be important in prognosis.

In this study, we have emphasised a synoptic approach to these diagnostic problems, including comparative clinical data and an elaborate histological work up of bone marrow trephine biopsies. Particular interest was focused on the histotopography of lymphoid aggregates in combination with immunohistochemical reactions in providing practical guidelines for diagnosis. However, the method of selection needs to be emphasised, because, in contrast with all other studies where routine staining techniques were applied, we started with the chloroacetate esterase reaction as the primary screening procedure. This selection criterion for case retrieval was chosen to detect even very small lymphoid infiltrates, in particular those adjacent to the bony trabeculae or generation zone of granulopoiesis which otherwise easily escape recognition. The diagnostic impact of the infiltration pattern also needs emphasis, since it included not only the endosteal localisation that indicated malignancy, but also subcortical involvement of the superficial age related adipose tissue (table 4). In contrast to the well defined and rather discrete outlines of benign lymphoid nodules, fat cells between questionable infiltrates characterised the interstitial spread or spillage of lymphoid cells and therefore suggested non-Hodgkin lymphoma (figs 2B, 3C). These relations between lymphoid nodules and surrounding bone marrow were most impressively demonstrable by applying enzyme (AS-D-chloroacetate esterase) and immunostaining techniques. Although in HIV myelopathy (AIDS), reactive lymphoid aggregates show an increase in finely dispersed fibres, non-Hodgkin lymphomas, with the exception of chronic lymphocytic leukaemia, usually showed a definite tendency to develop a moderate to significant accumulation of reticulin.

A conflict of opinion has emerged over whether monoclonality is definite proof of malignancy, particularly with respect to corresponding bone marrow lesions. It is not universally accepted that an accumulation of plasma cells with (monotypic) light chain restrictions implies malignancy, because not all monoclonal gammapathies are compatible with malignant myelomas. Moreover, there are

Table 4  Criteria for the differentiation between focal infiltrates of malignant lymphomas and reactive nodular lymphoid hyperplasia

<table>
<thead>
<tr>
<th>Variable</th>
<th>Malignant lymphoma</th>
<th>Benign lymphoid aggregate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of infiltrates in section profile</td>
<td>≥ 1 without germinal centres</td>
<td>≤ 3 with partial germinal centres (lymphoid follicles)</td>
</tr>
<tr>
<td>Histotopography</td>
<td>1. Paratrabeucular-endosteat (except CLL)</td>
<td>1. Central-perivascular</td>
</tr>
<tr>
<td></td>
<td>2. Subcortical in marrow spaces</td>
<td>2. Deep marrow spaces</td>
</tr>
<tr>
<td></td>
<td>3. Focal-nodular with interstitial spread (Indian file pattern)</td>
<td>3. Fairly defined margin</td>
</tr>
<tr>
<td>Reticulin fibres</td>
<td>Moderate to advanced (except CLL)</td>
<td>Borderline to minimal (except HIV myelopathy)</td>
</tr>
<tr>
<td>Immunohistochemistry</td>
<td>Uniform pattern with predominance of B or T lymphocytes; expression of monotypic (cytoplasmic) immunoglobulins</td>
<td>Polyclonal pattern with mixture of B and T lymphocytes; polyclonal expression of immunoglobulins</td>
</tr>
</tbody>
</table>

CLL, chronic lymphocytic leukaemia.
diagnostic problems regarding composite non-Hodgkin lymphomas—that is, T-cell-rich B cell lymphomas or an admixture of T cells in small B cell lymphomas. In routinely processed bone marrow tissue it may be difficult to demonstrate monoclonality, depending on the methods used, and consequently most studies have used frozen section material. The processing of bone marrow tissue in this study was restricted to easy to handle and reproducible techniques without immunohistochemical limitations. A comparative study on the different methods of identifying lymphoid lesions showed an advantage of formalin fixed, decalcified, and paraffin wax embedded trephine biopsies as opposed to plastic (methyl methacrylate) or frozen sections. By applying a particular set of antibodies to overcome the obstacles of cross reactivity (table 1), we succeeded in showing the predominantly uniform expression of a prevailing B cell or T cell population composing these lymphoid aggre-

Figure 2  Histotopography and immunohistochemistry of malignant lymphoma infiltrates in the bone marrow. Deficient margination (A) with interstitial lymphoid cell invasion between adipocytes (Giemsa) and conspicuous spillage of B lymphocytes (L26) into the surrounding haematopoiesis in CLL (B). Tapestry-like endosteal localisation of GB-CC lymphoma infiltrates (C–E) revealing an almost uniform expression of B cell markers (C, L26). Monoclonal antibodies directed against T cells (D, UCHL-1; E, MT1) are either negative or show, in addition to very few residual B lymphocytes, some cross reactivity with a few lymphohistiocytic cells. There is paratrabecular increase in reticulin fibres (F) in these lymphoma infiltrates (GB-CC). (Magnifications: A, B, F×308; C, D, E×146.)
gates in routinely processed bone marrow specimens. This is in keeping with a recently published systematically conducted immunohistological study on paraffin embedded bone marrow biopsies which also included lymphoproliferative disorders. However, critical re-evaluation of this distinctive feature showed the presence of bcl-2 in both benign as well as malignant lymphoid nodules. For this reason, the property of bcl-2 for differentiation remains questionable. Finally, depending on classification, comparative histology of non-Hodgkin lymphoma in lymph nodes and bone marrow showed disturbing discrepancies in several cases and thus confirmed previous studies in this field.

In non-Hodgkin lymphoma infiltrates of the bone marrow was described, while benign lymphoid nodules were claimed to lack this antigen. However, a consistent expression of the bcl-2 protein in all non-Hodgkin lymphoma infiltrates of the bone marrow was described, while benign lymphoid nodules were claimed to lack this antigen. However, a critical re-evaluation of this distinctive feature showed the presence of bcl-2 in both benign as well as malignant lymphoid nodules. For this reason, the property of bcl-2 for differentiation remains questionable.

Finally, depending on classification, comparative histology of non-Hodgkin lymphoma in lymph nodes and bone marrow showed disturbing discrepancies in several cases and thus confirmed previous studies in this field.

Figure 3  Immunohistochemistry of malignant lymphoma infiltrates (LPI subtype) in the bone marrow (A, B). There is an ill defined margination (A, L26; B, MT1) and an increase in reticulin fibres in these lesions (C). Lymphoid nodules consist of B lymphocytes (D, L26), while UCHL-1 (E) shows positive staining of a few lymphohistocytes, and MT1 (F) a negative reaction. Monoclonal expression of light chains of the k type is shown (G), contrasting negativity with an antibody directed against l light chains (H). (Magnifications: A, B ×145; C–F ×298; G, H ×467.)
particular, a high incidence of morphological discordance was observed with a more aggressive (large cell blastic) nodular subtype, in contrast with the findings in bone marrow. This aspect probably involves histological progress and transformation, with a change from low to high grade malignancy which may not occur simultaneously and at the same speed in lymph node and bone marrow tissue alike.

In conclusion, a synoptic approach using several distinctive features, particularly histotopography and immunohistochemistry, presents the most promising way to differentiate between reactive and neoplastic lymphoid nodules in the bone marrow. We are greatly indebted to Mrs B. Wonschick, and Mrs P. Schmitz for their excellent technical assistance.

Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma--a practical guideline.
J Thiele, T K Zirbes, H M Kvasnicka and R Fischer

_J Clin Pathol_ 1999 52: 294-300
doi: 10.1136/jcp.52.4.294

Updated information and services can be found at:
http://jcp.bmj.com/content/52/4/294

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/